Skip to main content
. 2022 Jun 13;30(3):453–461. doi: 10.5603/CJ.a2022.0123

Figure 1.

Figure 1

Algorithm for the use of anticoagulants in coronavirus disease 2019 (COVID-19) patients with ≤ 18 years who have already taken an anticoagulant. Heparin resistance in COVID-19: if the heparin dose is > 25 IU/kg/day and there is no activated partial thromboplastin clotting time prolongation anti-Xa monitoring at the level of 0.3–0.7 IU/mL; DD — D-dimer; ECMO — extracorporeal membrane oxygenation; PE — pulmonary embolism; VTE — venous thromboembolism.